dynavax technologies corp. - DVAX
DVAX
Close Chg Chg %
15.68 0.00 0.00%
Closed Market
15.68
0.00 (0.00%)
Volume: 1.62M
Last Updated:
Jan 21, 2026, 4:00 PM EDT
Company Overview: dynavax technologies corp. - DVAX
DVAX Key Data
| Open $15.56 | Day Range 15.56 - 15.69 |
| 52 Week Range 9.20 - 15.73 | Market Cap $1.84B |
| Shares Outstanding 117.43M | Public Float 116.47M |
| Beta 0.89 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.33 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.03M |
DVAX Performance
| 1 Week | 0.32% | ||
| 1 Month | 44.38% | ||
| 3 Months | 51.06% | ||
| 1 Year | 23.08% | ||
| 5 Years | 200.38% |
DVAX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About dynavax technologies corp. - DVAX
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
DVAX At a Glance
Dynavax Technologies Corp.
2100 Powell Street
Emeryville, California 94608
| Phone | 1-510-848-5100 | Revenue | 277.25M | |
| Industry | Biotechnology | Net Income | 27.31M | |
| Sector | Health Technology | 2024 Sales Growth | 19.356% | |
| Fiscal Year-end | 12 / 2025 | Employees | 405 | |
| View SEC Filings |
DVAX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 62.354 |
| Price to Sales Ratio | 6.142 |
| Price to Book Ratio | 2.684 |
| Price to Cash Flow Ratio | 25.60 |
| Enterprise Value to EBITDA | 316.383 |
| Enterprise Value to Sales | 4.485 |
| Total Debt to Enterprise Value | 0.205 |
DVAX Efficiency
| Revenue/Employee | 684,558.025 |
| Income Per Employee | 67,429.63 |
| Receivables Turnover | 5.867 |
| Total Asset Turnover | 0.28 |
DVAX Liquidity
| Current Ratio | 10.796 |
| Quick Ratio | 9.905 |
| Cash Ratio | 9.078 |
DVAX Profitability
| Gross Margin | 82.166 |
| Operating Margin | -1.487 |
| Pretax Margin | 11.129 |
| Net Margin | 9.85 |
| Return on Assets | 2.754 |
| Return on Equity | 4.481 |
| Return on Total Capital | 3.208 |
| Return on Invested Capital | 3.173 |
DVAX Capital Structure
| Total Debt to Total Equity | 42.63 |
| Total Debt to Total Capital | 29.889 |
| Total Debt to Total Assets | 25.796 |
| Long-Term Debt to Equity | 41.931 |
| Long-Term Debt to Total Capital | 29.398 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Dynavax Technologies Corp. - DVAX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 437.04M | 722.68M | 232.28M | 277.25M | |
Sales Growth
| +838.85% | +65.36% | -67.86% | +19.36% | |
Cost of Goods Sold (COGS) incl D&A
| 173.57M | 262.15M | 50.17M | 49.45M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 7.01M | 6.67M | 7.28M | 8.05M | |
Depreciation
| 7.01M | 6.67M | 7.28M | 8.05M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +901.71% | +51.03% | -80.86% | -1.44% | |
Gross Income
| 263.47M | 460.53M | 182.12M | 227.80M | |
Gross Income Growth
| +801.57% | +74.79% | -60.45% | +25.08% | |
Gross Profit Margin
| +60.28% | +63.73% | +78.40% | +82.17% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 130.48M | 175.78M | 216.16M | 231.92M | |
Research & Development
| 32.23M | 46.60M | 54.89M | 61.55M | |
Other SG&A
| 98.25M | 129.19M | 161.28M | 170.37M | |
SGA Growth
| +24.92% | +34.72% | +22.97% | +7.29% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 55.29M | 422.00K | 3.98M | |
EBIT after Unusual Expense
| 77.70M | 284.32M | (38.03M) | (4.12M) | |
Non Operating Income/Expense
| 11.00M | 16.71M | 40.42M | 41.77M | |
Non-Operating Interest Income
| 140.00K | 7.91M | 31.99M | 36.46M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 11.18M | 6.73M | 6.76M | 6.79M | |
Interest Expense Growth
| -41.37% | -39.76% | +0.37% | +0.55% | |
Gross Interest Expense
| 11.18M | 6.73M | 6.76M | 6.79M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 77.52M | 294.30M | (4.37M) | 30.86M | |
Pretax Income Growth
| +203.03% | +279.64% | -101.48% | +806.55% | |
Pretax Margin
| +17.74% | +40.72% | -1.88% | +11.13% | |
Income Tax
| 808.00K | 1.14M | 2.02M | 3.55M | |
Income Tax - Current - Domestic
| 605.00K | 732.00K | 1.35M | 2.62M | |
Income Tax - Current - Foreign
| 203.00K | 411.00K | 667.00K | 924.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | (4.57M) | (283.00K) | - |
Consolidated Net Income
| 72.14M | 292.87M | (6.39M) | 27.31M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 72.14M | 292.87M | (6.39M) | 27.31M | |
Net Income Growth
| +195.89% | +305.96% | -102.18% | +527.44% | |
Net Margin Growth
| +16.51% | +40.53% | -2.75% | +9.85% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 72.14M | 292.87M | (6.39M) | 27.31M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 72.14M | 292.87M | (6.39M) | 27.31M | |
EPS (Basic)
| 0.6205 | 2.3171 | -0.0496 | 0.21 | |
EPS (Basic) Growth
| +183.09% | +273.42% | -102.14% | +523.39% | |
Basic Shares Outstanding
| 116.26M | 126.40M | 128.73M | 130.05M | |
EPS (Diluted)
| 0.5424 | 1.9656 | -0.0496 | 0.2048 | |
EPS (Diluted) Growth
| +172.63% | +262.39% | -102.52% | +512.90% | |
Diluted Shares Outstanding
| 133.01M | 150.80M | 128.73M | 133.34M | |
EBITDA
| 140.00M | 291.41M | (26.77M) | 3.93M | |
EBITDA Growth
| +312.49% | +108.15% | -109.19% | +114.68% | |
EBITDA Margin
| +32.03% | +40.32% | -11.53% | +1.42% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 22.00 | |
| Number of Ratings | 4 | Current Quarters Estimate | 0.077 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 0.528 | |
| Last Quarter’s Earnings | 0.08 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.361 | Next Fiscal Year Estimate | 0.766 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 3 | 3 |
| Mean Estimate | 0.08 | 0.17 | 0.53 | 0.77 |
| High Estimates | 0.14 | 0.24 | 0.65 | 0.96 |
| Low Estimate | -0.02 | 0.08 | 0.33 | 0.44 |
| Coefficient of Variance | 110.23 | 47.45 | 32.81 | 37.05 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 2 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Dynavax Technologies Corp. - DVAX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Dynavax Technologies Corp. - DVAX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 30, 2025 | David F. Novack President & COO | 92,663 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | Ryan Spencer CEO and Director; Director | 417,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 30, 2025 | David F. Novack President & COO | 85,655 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | David F. Novack President & COO | 166,528 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | David F. Novack President & COO | 37,576 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | David F. Novack President & COO | 22,620 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | David F. Novack President & COO | 63,344 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.38 per share | 974,230.72 |
| Dec 30, 2025 | David F. Novack President & COO | 111,451 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15.49 per share | 1,726,375.99 |
| Dec 30, 2025 | David F. Novack President & COO | 141,451 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.47 per share | 1,480,991.97 |
| Dec 30, 2025 | David F. Novack President & COO | 131,451 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.8 per share | 893,866.80 |
| Dec 30, 2025 | David F. Novack President & COO | 111,451 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | John L. Slebir SVP General Counsel | 71,328 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 30, 2025 | David F. Novack President & COO | 70,043 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 30, 2025 | Ryan Spencer CEO and Director; Director | 472,455 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | Ryan Spencer CEO and Director; Director | 517,788 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | Joseph Metzinger VP, Chief Accounting Officer | 25,455 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | John L. Slebir SVP General Counsel | 28,282 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | John L. Slebir SVP General Counsel | 16,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 30, 2025 | John L. Slebir SVP General Counsel | 69,634 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.38 per share | 1,070,970.92 |
| Dec 30, 2025 | John L. Slebir SVP General Counsel | 102,136 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |